2001 MARKET STREET, PHILADELPHIA, PA
Investor Presentation
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Context Therapeutics Increases Authorized Shares to 300 Million
Enters into License Agreement Amendment with BioAtla for CT-202
Other Events
Annual Report to Security Holders
CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership